Description

Sinflorix Vaccines (pneumococcal polysaccharide) suspension for injection 1 dose of 0.5 ml №1 in a pre-filled disposable syringe

Ingredients

Each 0.5 ml dose contains pneumococcal polysaccharides from 13 serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 19A, 22F, and 23F).

Dosage

The recommended dosage is a single 0.5 ml injection administered subcutaneously.

Indications

Sinflorix Vaccines are indicated for active immunization against invasive pneumococcal disease caused by the serotypes included in the vaccine.

Contraindications

Do not administer Sinflorix Vaccines to individuals with a known hypersensitivity to any component of the vaccine.

Directions

The vaccine should be administered by healthcare professionals according to standard vaccination practices.

Scientific Evidence

Sinflorix Vaccines have demonstrated efficacy in preventing invasive pneumococcal disease in clinical trials. The vaccine’s formulation, containing a combination of pneumococcal polysaccharides, has shown to induce a robust immune response against the targeted serotypes.

Furthermore, studies have indicated that Sinflorix Vaccines provide long-lasting protection against pneumococcal infections, reducing the incidence of severe disease and associated complications.

Additional Information

It is essential to adhere to the recommended vaccination schedule to ensure optimal protection against pneumococcal disease. Consult with a healthcare provider to determine the most suitable vaccination plan based on individual risk factors.

Patients should be informed about the benefits of Sinflorix Vaccines in preventing potentially life-threatening pneumococcal infections and the importance of vaccination in maintaining public health.